Moderna, Inc.’s shares jumped more than 8% in after-hours trading on 11 August after the vaccine developer announced it had reached an agreement with the US government to supply an initial 100 million doses of its mRNA coronavirus candidate mRNA-1273.
Up to $1.525bn has been awarded for the manufacture and delivery of this first tranche of doses - including incentive...







